Yu‐Han Gao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yu‐Han Gao has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Jian Li
Department of Hematology, Peking Union Medical College Hospital, Beijing, China
12 shared publications - Lu Zhang
Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
12 shared publications - Si‐Yuan Li
Department of Hematology Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China
7 shared publications - Yue Dang
Department of Hematology Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China
5 shared publications - Ming-Hui Duan
Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
4 shared publications - Yan-Ting Liu
State Key Laboratory of Complex Severe and Rare Diseases, Critical and Emergency Pharmaceuticals & Medical Devices Innovation Lab, Department of Emergency, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 1 Shuaifuyuan, Wangfujing, Dongcheng District, Beijing 100730, China
4 shared publications
Latest Publications
- Open Access
- 20 February 2026
- Published by Wiley in HemaSphere
- Vol. 10 (2)
Is “severe” idiopathic multicentric Castleman disease (iMCD)‐idiopathic plasmacytic lymphadenopathy (IPL) really severe?
- 20 February 2026
- Published by Wiley in HemaSphere
- Vol. 10 (2)
Open AccessIs “severe” idiopathic multicentric Castleman disease (iMCD)‐idiopathic plasmacytic lymphadenopathy (IPL) really severe?
- Open Access
- 12 February 2025
- Published by Galenos Yayinevi in Turkish Journal of Hematology
- Vol. 42 (1) , 1-8
TAFRO Syndrome Without Pathology Supporting Castleman Disease: To Be Treated as iMCD-TAFRO or a Distinct Disease Entity?
TAFRO syndrome, entailing thrombocytopenia, anasarca, fever, reticulin fibrosis, and organomegaly, was previously considered a subtype of idiopathic multicentric Castleman disease (iMCD-TAFRO), with the diagnosis requiring pathology supporting Castleman disease. However, lymph node biopsies may be difficult for TAFRO patients (TAFRO without pathological evidence: TAFRO-w/op-iMCD), and sometimes these biopsies do not confirm iMCD (TAFRO-w/o-iMCD). We aimed to compare the clinical features and prognosis of TAFRO subgroups. We retrospectively analyzed the cases of 50 iMCD-TAFRO and 11 TAFRO-w/o-iMCD patients treated from May 2015 to April 2024. The groups showed no significant differences in clinical presentation or laboratory data. Both groups of patients were treated with iMCD-targeted strategies addressing cytokine storms. With a median follow-up of 21.4 (range: 0.5-107.0) months, there were no significant differences between iMCD-TAFRO and TAFRO-w/o-iMCD patients in 3-month response rate (72.1% vs. 88.9%, p=0.525), 6-month response rate (70.0% vs. 83.3%, p=0.849), or best overall response rate (77.6% vs. 90.0%, p=0.645). The estimated 3-year progression-free survival rate (65.8% vs. 90.0%, log-rank p=0.163) and the estimated 3-year overall survival rate (77.0% vs. 100%, log-rank p=0.145) were also not significantly different. Univariate logistic analysis showed that decreased estimated glomerular filtration rate (<60 mL/min/1.73 m2) was associated with an increased risk of disease progression (odds ratio: 5.556, 95% confidence interval: 1.653-18.672, p=0.006). iMCD-TAFRO and TAFRO-w/o-iMCD could be considered overlapping entities and these patients should be treated promptly, targeting cytokine storms with similar strategies for each group of patients.
- 12 February 2025
- Published by Galenos Yayinevi in Turkish Journal of Hematology
- Vol. 42 (1) , 1-8
Open AccessTAFRO Syndrome Without Pathology Supporting Castleman Disease: To Be Treated as iMCD-TAFRO or a Distinct Disease Entity?
TAFRO syndrome, entailing thrombocytopenia, anasarca, fever, reticulin fibrosis, and organomegaly, was previously considered a subtype of idiopathic multicentric Castleman disease (iMCD-TAFRO), with the diagnosis requiring pathology supporting Castleman disease. However, lymph node biopsies may be difficult for TAFRO patients (TAFRO without pathological evidence: TAFRO-w/op-iMCD), and sometimes these biopsies do not confirm iMCD (TAFRO-w/o-iMCD). We aimed to compare the clinical features and prognosis of TAFRO subgroups. We retrospectively analyzed the cases of 50 iMCD-TAFRO and 11 TAFRO-w/o-iMCD patients treated from May 2015 to April 2024. The groups showed no significant differences in clinical presentation or laboratory data. Both groups of patients were treated with iMCD-targeted strategies addressing cytokine storms. With a median follow-up of 21.4 (range: 0.5-107.0) months, there were no significant differences between iMCD-TAFRO and TAFRO-w/o-iMCD patients in 3-month response rate (72.1% vs. 88.9%, p=0.525), 6-month response rate (70.0% vs. 83.3%, p=0.849), or best overall response rate (77.6% vs. 90.0%, p=0.645). The estimated 3-year progression-free survival rate (65.8% vs. 90.0%, log-rank p=0.163) and the estimated 3-year overall survival rate (77.0% vs. 100%, log-rank p=0.145) were also not significantly different. Univariate logistic analysis showed that decreased estimated glomerular filtration rate (<60 mL/min/1.73 m2) was associated with an increased risk of disease progression (odds ratio: 5.556, 95% confidence interval: 1.653-18.672, p=0.006). iMCD-TAFRO and TAFRO-w/o-iMCD could be considered overlapping entities and these patients should be treated promptly, targeting cytokine storms with similar strategies for each group of patients.
- 3 January 2025
- Published by Wiley in American Journal of Hematology
- Vol. 100 (3) , 539-541
Clinical Characteristics and Prognosis of Pediatric Idiopathic Multicentric Castleman Disease
- 3 January 2025
- Published by Wiley in American Journal of Hematology
- Vol. 100 (3) , 539-541
Clinical Characteristics and Prognosis of Pediatric Idiopathic Multicentric Castleman Disease
- 29 December 2024
- Published by Wiley in British Journal of Haematology
- Vol. 206 (4) , 1129-1135
Unicentric Castleman disease complicated with bronchiolitis obliterans: A single‐centre retrospective study from China
Summary: Bronchiolitis obliterans (BO) is a rare and life‐threatening complication of unicentric Castleman disease (UCD), which is considered the leading cause of death in UCD. However, few studies focused on the characteristics of UCD patients complicated with BO. This single‐centre, retrospective study of 281 patients diagnosed with UCD identified 18 patients (6.4%) with BO. UCD‐BO patients had a significantly lower age at UCD diagnosis than the UCD without BO group. 94.4% of UCD‐BO patients had deep lymph nodes involvement and 83.3% of them had paraneoplastic pemphigus, which were both significantly higher than UCD without BO. Median forced expiratory volume in 1 s of predicted was 20.9% (10%–41.9%) and 83.3% patients had severe BO. All patients underwent complete resection for UCD. 61.1% patients developed BO after surgery. UCD‐BO patients had a poorer overall survival than UCD without BO. Among severe BO, 11 patients did not receive lung transplantation and two of them died, with 62.5% (95% CI, 20.8%–100%) of estimated 5‐year overall survival. Four patients underwent lung transplantation and they all survived. UCD‐BO patients had distinct clinical identity. Complete resection could neither alleviate BO nor prevent BO progression. Lung transplantation is a vital treatment for improving prognosis for patients with severe BO.
- 29 December 2024
- Published by Wiley in British Journal of Haematology
- Vol. 206 (4) , 1129-1135
Unicentric Castleman disease complicated with bronchiolitis obliterans: A single‐centre retrospective study from China
Summary: Bronchiolitis obliterans (BO) is a rare and life‐threatening complication of unicentric Castleman disease (UCD), which is considered the leading cause of death in UCD. However, few studies focused on the characteristics of UCD patients complicated with BO. This single‐centre, retrospective study of 281 patients diagnosed with UCD identified 18 patients (6.4%) with BO. UCD‐BO patients had a significantly lower age at UCD diagnosis than the UCD without BO group. 94.4% of UCD‐BO patients had deep lymph nodes involvement and 83.3% of them had paraneoplastic pemphigus, which were both significantly higher than UCD without BO. Median forced expiratory volume in 1 s of predicted was 20.9% (10%–41.9%) and 83.3% patients had severe BO. All patients underwent complete resection for UCD. 61.1% patients developed BO after surgery. UCD‐BO patients had a poorer overall survival than UCD without BO. Among severe BO, 11 patients did not receive lung transplantation and two of them died, with 62.5% (95% CI, 20.8%–100%) of estimated 5‐year overall survival. Four patients underwent lung transplantation and they all survived. UCD‐BO patients had distinct clinical identity. Complete resection could neither alleviate BO nor prevent BO progression. Lung transplantation is a vital treatment for improving prognosis for patients with severe BO.
- Open Access
- 6 November 2024
- Published by Galenos Yayinevi in Turkish Journal of Hematology
- Vol. 41 (4) , 283-285
Rapid relapse of idiopathic multicentric Castleman disease after siltuximab discontinuation in a case with complete remission for more than 10 years
- 6 November 2024
- Published by Galenos Yayinevi in Turkish Journal of Hematology
- Vol. 41 (4) , 283-285
Open AccessRapid relapse of idiopathic multicentric Castleman disease after siltuximab discontinuation in a case with complete remission for more than 10 years
- 15 October 2024
- Published by Wiley in British Journal of Haematology
- Vol. 206 (1) , 152-158
Efficacy and safety of orelabrutinib in relapsed/refractory idiopathic multicentric Castleman disease: A single‐centre, retrospective study
Summary: Idiopathic multicentric Castleman disease (iMCD) is a rare and heterogeneous lymphoproliferative disorder that lacks standardised treatment options for patients with refractory or relapsed (r/r) disease. Blocking Bruton's tyrosine kinase (BTK) has emerged as a promising therapeutic approach for iMCD without depleting B cells. This single‐centre, retrospective study enrolled 10 patients with r/r iMCD who were treated with orelabrutinib, a novel, next‐generation BTK inhibitor. The median age at orelabrutinib initiation was 48 (range: 31–58) years. The overall response rate was 70% (7/10 patients, 95% CI: 34.8–93.3), with 20% (n = 2) achieving complete response and 50% (n = 5) achieving partial response. The median time to response was 9.8 (range: 5.9–20.5) months. Patients in the non‐responder group also demonstrated a continuous improvement in haemoglobin (91–105 g/L) and albumin (32–38 g/L) levels at month 12 of treatment despite not fulfilling response criteria. No grade 3 or higher adverse events occurred during the median time to the next treatment of 29.0 (range: 15.0–36.2) months. No patient mortality was recorded during the median follow‐up duration of 32.8 (range: 15.0–36.9) months. In conclusion, orelabrutinib is a safe and effective regimen for r/r iMCD.
- 15 October 2024
- Published by Wiley in British Journal of Haematology
- Vol. 206 (1) , 152-158
Efficacy and safety of orelabrutinib in relapsed/refractory idiopathic multicentric Castleman disease: A single‐centre, retrospective study
Summary: Idiopathic multicentric Castleman disease (iMCD) is a rare and heterogeneous lymphoproliferative disorder that lacks standardised treatment options for patients with refractory or relapsed (r/r) disease. Blocking Bruton's tyrosine kinase (BTK) has emerged as a promising therapeutic approach for iMCD without depleting B cells. This single‐centre, retrospective study enrolled 10 patients with r/r iMCD who were treated with orelabrutinib, a novel, next‐generation BTK inhibitor. The median age at orelabrutinib initiation was 48 (range: 31–58) years. The overall response rate was 70% (7/10 patients, 95% CI: 34.8–93.3), with 20% (n = 2) achieving complete response and 50% (n = 5) achieving partial response. The median time to response was 9.8 (range: 5.9–20.5) months. Patients in the non‐responder group also demonstrated a continuous improvement in haemoglobin (91–105 g/L) and albumin (32–38 g/L) levels at month 12 of treatment despite not fulfilling response criteria. No grade 3 or higher adverse events occurred during the median time to the next treatment of 29.0 (range: 15.0–36.2) months. No patient mortality was recorded during the median follow‐up duration of 32.8 (range: 15.0–36.9) months. In conclusion, orelabrutinib is a safe and effective regimen for r/r iMCD.
- 10 June 2024
- Published by Wiley in British Journal of Haematology
- Vol. 205 (3) , 1208-1211
Successful treatment of relapsed idiopathic multicentric Castleman disease–idiopathic plasmacytic lymphadenopathy with orelabrutinib monotherapy: A case report
- 10 June 2024
- Published by Wiley in British Journal of Haematology
- Vol. 205 (3) , 1208-1211
Successful treatment of relapsed idiopathic multicentric Castleman disease–idiopathic plasmacytic lymphadenopathy with orelabrutinib monotherapy: A case report
- 1 May 2024
- Published by Springer Nature in Annals of Hematology
- Vol. 103 (10) , 4223-4230
Sirolimus is effective for refractory/relapsed idiopathic multicentric Castleman disease: A single-center, retrospective study
Refractory/relapsed idiopathic multicentric Castleman disease (R/R iMCD) has limited treatment options. With studies showing increased mTOR activation in iMCD patients, sirolimus becomes an attractive and promising therapy for R/R iMCD. Here we report the results of a retrospective study involving 26 R/R iMCD patients treated with sirolimus-containing regimen. The median age at sirolimus initiation was 40.5 years (23–60), with a median prior treatment line of 2 (1–5). 18 patients (69.2%) achieved symptomatic and biochemical response, with a median time to at least overall partial remission of 1.9 months (0.5–14.6). The median follow-up time from sirolimus initiation was 11.7 months (1.6–50.7) and the median time to next treatment (TTNT) was 46.2 months. No patients died at the end of follow-up. Most of the patients in the cohort are in ongoing responses and continue sirolimus therapy. Sirolimus is well tolerated with minor adverse effects. In conclusion, sirolimus is effective for R/R iMCD patients with good tolerance.
- 1 May 2024
- Published by Springer Nature in Annals of Hematology
- Vol. 103 (10) , 4223-4230
Sirolimus is effective for refractory/relapsed idiopathic multicentric Castleman disease: A single-center, retrospective study
Refractory/relapsed idiopathic multicentric Castleman disease (R/R iMCD) has limited treatment options. With studies showing increased mTOR activation in iMCD patients, sirolimus becomes an attractive and promising therapy for R/R iMCD. Here we report the results of a retrospective study involving 26 R/R iMCD patients treated with sirolimus-containing regimen. The median age at sirolimus initiation was 40.5 years (23–60), with a median prior treatment line of 2 (1–5). 18 patients (69.2%) achieved symptomatic and biochemical response, with a median time to at least overall partial remission of 1.9 months (0.5–14.6). The median follow-up time from sirolimus initiation was 11.7 months (1.6–50.7) and the median time to next treatment (TTNT) was 46.2 months. No patients died at the end of follow-up. Most of the patients in the cohort are in ongoing responses and continue sirolimus therapy. Sirolimus is well tolerated with minor adverse effects. In conclusion, sirolimus is effective for R/R iMCD patients with good tolerance.
- 28 March 2024
- Published by Springer Nature in International Journal of Hematology
- Vol. 119 (6) , 631-637
A prospective study of zanubrutinib, a Bruton tyrosine kinase inhibitor, in relapsed/refractory idiopathic multicentric Castleman disease
Relapsed and refractory (R/R) idiopathic multicentric Castleman disease (iMCD) is a clinical challenge with no standard treatment. In this preliminary clinical trial, we investigated the efficacy and safety profiles of a Bruton tyrosine kinase inhibitor (BTKi), zanubrutinib, in patients with R/R iMCD. The primary endpoint was the overall response rate at Week 12 according to the Castleman Disease Collaborative Network (CDCN) response criteria. The trial was terminated early due to a lack of treatment response in the first enrolled 5 patients. Although 3 patients achieved symptomatic response, none of the 5 patients had an overall response by Week 12. One patient had progressive disease and the other 4 had stable disease. The study drug was well tolerated without grade 2 or higher adverse events. Our findings suggest that BTKi therapy is not effective for iMCD, and further attempts at single-agent therapy with zanubrutinib or other BTKis for iMCD should be considered with caution and probably avoided. This trial was registered at www.clinialtrials.gov as #NCT04743687.
- 28 March 2024
- Published by Springer Nature in International Journal of Hematology
- Vol. 119 (6) , 631-637
A prospective study of zanubrutinib, a Bruton tyrosine kinase inhibitor, in relapsed/refractory idiopathic multicentric Castleman disease
Relapsed and refractory (R/R) idiopathic multicentric Castleman disease (iMCD) is a clinical challenge with no standard treatment. In this preliminary clinical trial, we investigated the efficacy and safety profiles of a Bruton tyrosine kinase inhibitor (BTKi), zanubrutinib, in patients with R/R iMCD. The primary endpoint was the overall response rate at Week 12 according to the Castleman Disease Collaborative Network (CDCN) response criteria. The trial was terminated early due to a lack of treatment response in the first enrolled 5 patients. Although 3 patients achieved symptomatic response, none of the 5 patients had an overall response by Week 12. One patient had progressive disease and the other 4 had stable disease. The study drug was well tolerated without grade 2 or higher adverse events. Our findings suggest that BTKi therapy is not effective for iMCD, and further attempts at single-agent therapy with zanubrutinib or other BTKis for iMCD should be considered with caution and probably avoided. This trial was registered at www.clinialtrials.gov as #NCT04743687.
- Open Access
- 4 March 2024
- Published by Galenos Yayinevi in Turkish Journal of Hematology
- Vol. 41 (1) , 61-63
Ruxolitinib for the Treatment of Refractory Idiopathic Multicentric Castleman Disease: A Case Report
- 4 March 2024
- Published by Galenos Yayinevi in Turkish Journal of Hematology
- Vol. 41 (1) , 61-63
Open AccessRuxolitinib for the Treatment of Refractory Idiopathic Multicentric Castleman Disease: A Case Report